Investor Relations

Investor Relations

BrainsWay is an industry leader in the field of transcranial magnetic stimulation (TMS).  BrainsWay’s flagship Deep TMS technology is a non-invasive, well-tolerated outpatient treatment, clinically proven to treat psychiatric and neurological conditions. 

BrainsWay has received FDA-clearance for both major depression (MDD) and obsessive compulsive disorder (OCD- De Novo) and is developing more applications outside of the US.  The company also has approval in Canada, Japan and other Asian countries. BrainsWay continues to push the TMS envelope with multiple clinical studies and further research into novel indications.

BrainsWay has an experienced business and development management team, as well as the backing of key scientific opinion leaders.

BrainsWay was founded in 2003 and began trading on the NASDAQ in 2019 under the symbol BWAY.

Latest releases
April 13, 2020
BrainsWay Announces Preliminary Revenue Range for First Quarter of 2020
PATTERSON, N.J., April 13, 2020 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive treatment of brain disorders, today announced a preliminary, unaudited revenue range for the first quarter ended March 31, 2020.

Questions for the Investor Relations Department can be submitted through the form below.

Fields marked with an * are required.

For more information please contact:

Mr. Hadar Levy, CFO

Office Tel +972-2-647-6010

Mobile +972-54-5699133

Fax +972-2-581-2517

US: +1-844-386-7001  or 1-844-DTMS-001

Email hadarl@brainsway.com

Data Provided by Refinitiv. Minimum 15 minutes delayed.